IS2372B - Tetrasólafleiður og aðferðir til að meðhöndla efnaskiptatengda sjúkdóma sem þeim tengjast - Google Patents

Tetrasólafleiður og aðferðir til að meðhöndla efnaskiptatengda sjúkdóma sem þeim tengjast

Info

Publication number
IS2372B
IS2372B IS8481A IS8481A IS2372B IS 2372 B IS2372 B IS 2372B IS 8481 A IS8481 A IS 8481A IS 8481 A IS8481 A IS 8481A IS 2372 B IS2372 B IS 2372B
Authority
IS
Iceland
Prior art keywords
methods
disorders associated
metabolic disorders
treating metabolic
tetrazole derivatives
Prior art date
Application number
IS8481A
Other languages
English (en)
Other versions
IS8481A (is
Inventor
Semple Graeme
Schrader Thomas
J. Skinner Philip
L. Colletti Steven
Gharbaoui Tawfik
E. Imbriglio Jason
Jung Jae-Kyu
Liang Rui
Raghavan Subharekha
Schmidt Darby
R. Tata James
Original Assignee
Arena Pharmaceuticals, Inc.
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharmaceuticals, Inc., Merck & Co., Inc. filed Critical Arena Pharmaceuticals, Inc.
Publication of IS8481A publication Critical patent/IS8481A/is
Publication of IS2372B publication Critical patent/IS2372B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS8481A 2003-10-31 2006-05-24 Tetrasólafleiður og aðferðir til að meðhöndla efnaskiptatengda sjúkdóma sem þeim tengjast IS2372B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51623803P 2003-10-31 2003-10-31
PCT/US2004/035927 WO2005044816A1 (en) 2003-10-31 2004-10-29 Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof

Publications (2)

Publication Number Publication Date
IS8481A IS8481A (is) 2006-05-24
IS2372B true IS2372B (is) 2008-06-15

Family

ID=34572875

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8481A IS2372B (is) 2003-10-31 2006-05-24 Tetrasólafleiður og aðferðir til að meðhöndla efnaskiptatengda sjúkdóma sem þeim tengjast

Country Status (37)

Country Link
US (2) US8637555B2 (is)
EP (2) EP1683794A1 (is)
JP (2) JP4533898B2 (is)
KR (1) KR100850591B1 (is)
CN (1) CN1867562B (is)
AR (1) AR046611A1 (is)
AT (1) ATE328880T1 (is)
AU (1) AU2004287861B2 (is)
BR (1) BRPI0415631A (is)
CA (1) CA2539985C (is)
CO (1) CO5690551A2 (is)
CR (1) CR8270A (is)
CY (1) CY1105479T1 (is)
DE (1) DE602004001134T2 (is)
DK (1) DK1599469T3 (is)
EA (1) EA011484B1 (is)
EC (1) ECSP066529A (is)
ES (1) ES2267077T3 (is)
GE (1) GEP20094801B (is)
HR (1) HRP20060286T3 (is)
IL (1) IL174042A0 (is)
IS (1) IS2372B (is)
MA (1) MA28171A1 (is)
MX (1) MXPA06004556A (is)
MY (1) MY140410A (is)
NO (1) NO20062509L (is)
NZ (1) NZ546285A (is)
PE (1) PE20050483A1 (is)
PL (1) PL1599469T3 (is)
PT (1) PT1599469E (is)
RS (1) RS20060290A (is)
SI (1) SI1599469T1 (is)
TN (1) TNSN06150A1 (is)
TW (1) TWI258478B (is)
UA (1) UA86783C2 (is)
WO (1) WO2005044816A1 (is)
ZA (2) ZA200603419B (is)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1603585A2 (en) 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
PE20050483A1 (es) 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
JP2007512346A (ja) * 2003-11-21 2007-05-17 アリーナ ファーマシューティカルズ， インコーポレイテッド ４−オキソ−４，５−ジヒドロ−フラン−２−カルボン酸誘導体およびその代謝関連障害の処置方法
US20070244107A1 (en) * 2004-08-25 2007-10-18 Waters M Gerard Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
AU2005305086A1 (en) * 2004-11-05 2006-05-18 Arena Pharmaceuticals, Inc. Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
WO2006114581A1 (en) * 2005-04-28 2006-11-02 Merck Sharp & Dohme Limited A process for the preparation of tetrazolyltetrahydrocyclopentapyrazoles
CA2611552A1 (en) 2005-06-28 2007-01-04 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
DE102006021733A1 (de) * 2006-05-09 2007-11-22 Bayer Healthcare Ag 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
CA2878625A1 (en) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
EP3760629A1 (en) 2013-02-21 2021-01-06 Adverio Pharma GmbH Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate
JP6453216B2 (ja) * 2013-07-23 2019-01-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ縮合環化合物
CN103755637A (zh) * 2013-12-26 2014-04-30 平湖优康药物研发有限公司 一种医药中间体1,4,5,6-四氢-3-环戊并吡唑甲腈的合成工艺
US12086719B2 (en) * 2019-10-11 2024-09-10 Royal Bank Of Canada System and method of machine learning using embedding networks

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02178263A (ja) * 1988-12-27 1990-07-11 Kaken Pharmaceut Co Ltd アザアズレン誘導体、その製造法およびそれを有効成分とする抗アレルギー剤および抗炎症剤
US5134155A (en) 1991-08-08 1992-07-28 Ortho Pharmaceutical Corporation Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-coA reductase inhibitors
US5948786A (en) 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
AU730224B2 (en) 1996-12-23 2001-03-01 Du Pont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US6506757B1 (en) 1998-03-10 2003-01-14 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
MXPA02008801A (es) 2000-03-09 2003-07-07 Ono Pharmaceutical Co Derivados de indol, proceso para la preparacion de los mismos y su uso.
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
US6699997B2 (en) 2000-06-28 2004-03-02 Teva Pharmaceutical Industries Ltd. Carvedilol
IL153111A0 (en) 2000-06-30 2003-06-24 Glaxo Group Ltd Quinazoline ditosylate salt compounds
US6410583B1 (en) 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
DE10057751A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Carbamat-substituierte Pyrazolopyridinderivate
ES2272712T3 (es) 2001-05-23 2007-05-01 Merck Frosst Canada Ltd. Derivados de dihidropirrolo-1,2-aiindol y tetrahidropirido -1,2-aiindol como antagonistas de receptores de prostaglandina d2.
DK1397351T3 (da) 2001-06-01 2010-01-18 Hoffmann La Roche Pyrimidin-, triazin- og pyrazinderivater som glutamatreceptorer
HUP0401711A3 (en) 2001-06-26 2009-07-28 Bristol Myers Squibb Co N-heterocyclic inhibitors of tnf-alpha and pharmaceutical compositions containing them
JP3968076B2 (ja) 2001-06-27 2007-08-29 アールエス テック コーポレイション 新しいキラルサレン化合物、キラルサレン触媒及びこれを利用したラセミックエポキシ化合物からキラル化合物を製造する方法
CA2459515A1 (en) 2001-09-07 2003-03-20 Kazuhiko Torisu Indole derivatives
DE10148617A1 (de) 2001-09-25 2003-04-24 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
MXPA04009095A (es) 2002-03-19 2004-12-06 Ono Pharmaceutical Co Compuesto de acido carboxilico y agente farmaceutico que comprende el compuesto como ingrediente activo.
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
AU2003282679A1 (en) 2002-10-04 2004-05-04 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
EP1551403B1 (en) * 2002-10-10 2009-04-29 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazone-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia
DE10261131A1 (de) 2002-12-20 2004-07-01 Grünenthal GmbH Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
AU2004260636A1 (en) 2003-06-13 2005-02-10 Arena Pharmaceuticals, Inc. 5-substituted 2H-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor RUP25 for the treatment of dyslipidemia and related diseases
GB0319126D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
GB0319124D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
PE20050483A1 (es) 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
CA2556073C (en) 2004-02-14 2012-01-10 Smithkline Beecham Corporation 8-chloro-1,3-disubstituted xanthine derivatives as hm74a receptor modulators
US20070244107A1 (en) 2004-08-25 2007-10-18 Waters M Gerard Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
AU2005305086A1 (en) 2004-11-05 2006-05-18 Arena Pharmaceuticals, Inc. Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
WO2006114581A1 (en) 2005-04-28 2006-11-02 Merck Sharp & Dohme Limited A process for the preparation of tetrazolyltetrahydrocyclopentapyrazoles

Also Published As

Publication number Publication date
US20060217562A1 (en) 2006-09-28
EP1599469B1 (en) 2006-06-07
NO20062509L (no) 2006-06-26
HK1076468A1 (en) 2006-01-20
IL174042A0 (en) 2006-08-01
DK1599469T3 (da) 2006-10-09
KR20060073974A (ko) 2006-06-29
AU2004287861A1 (en) 2005-05-19
IS8481A (is) 2006-05-24
MY140410A (en) 2009-12-31
US8637555B2 (en) 2014-01-28
PL1599469T3 (pl) 2006-10-31
JP4533898B2 (ja) 2010-09-01
TNSN06150A1 (en) 2007-11-15
AR046611A1 (es) 2005-12-14
HRP20060286T3 (en) 2007-03-31
KR100850591B1 (ko) 2008-08-05
WO2005044816A1 (en) 2005-05-19
DE602004001134D1 (de) 2006-07-20
MA28171A1 (fr) 2006-09-01
RS20060290A (sr) 2008-11-28
PE20050483A1 (es) 2005-08-25
CN1867562A (zh) 2006-11-22
EA200600879A1 (ru) 2006-10-27
AU2004287861B2 (en) 2008-08-14
TW200530221A (en) 2005-09-16
BRPI0415631A (pt) 2006-12-12
JP2010163448A (ja) 2010-07-29
CN1867562B (zh) 2011-07-13
EP1683794A1 (en) 2006-07-26
CY1105479T1 (el) 2010-07-28
JP2007509181A (ja) 2007-04-12
NZ546285A (en) 2010-04-30
SI1599469T1 (sl) 2006-10-31
EA011484B1 (ru) 2009-04-28
CR8270A (es) 2006-10-06
MXPA06004556A (es) 2006-07-06
ECSP066529A (es) 2006-10-10
EP1599469A1 (en) 2005-11-30
ES2267077T3 (es) 2007-03-01
CA2539985C (en) 2010-02-16
CA2539985A1 (en) 2005-05-19
CO5690551A2 (es) 2006-10-31
ATE328880T1 (de) 2006-06-15
GEP20094801B (en) 2009-10-26
DE602004001134T2 (de) 2007-04-19
UA86783C2 (ru) 2009-05-25
ZA200606203B (en) 2007-04-25
US20070072924A1 (en) 2007-03-29
PT1599469E (pt) 2006-10-31
ZA200603419B (en) 2006-10-25
TWI258478B (en) 2006-07-21

Similar Documents

Publication Publication Date Title
IL188988A0 (en) Methods for preventing and treating metabolic disorders and new pyrazole-o-glycoside derivatives
NO20032220D0 (no) Löfteverktöy II og fremgangsmåte for anvendelse av samme
DK3589081T3 (da) Effektstyringfremgangsmåder og -apparat
GB0822148D0 (en) Methods and apparatus
IL180251A0 (en) Methods and reagents for the treatment of metabolic disorders
IL184047A0 (en) Methods and compositions for treating amyloid-related diseases
SI1725253T1 (sl) Zdravila in metode za zdravljenje glavobola
IL187480A0 (en) Method and composition for treating inflammatory disorders
IS2372B (is) Tetrasólafleiður og aðferðir til að meðhöndla efnaskiptatengda sjúkdóma sem þeim tengjast
GB0526291D0 (en) Therapeutic method
EP1958177A4 (en) PERFUSION PROCESS AND DEVICE
IL179864A0 (en) Compounds and methods for treating seizure and paroxysmal disorders
GB0515160D0 (en) Transaction management apparatus and method
DE602005001520D1 (de) Zeiteinstellungssystem und Zeiteinstellungsverfahren
NO20053593D0 (no) Arylalkylkarbamat-derivater, fremgangsmate og anvendelse derav i terapi
NO20044012D0 (no) Fremgangsmate og et system
FI20055682A0 (fi) Läpivientiosa sekä menetelmä
NO20050503D0 (no) Fremgangsmate og anordning
EP1804703A4 (en) CRYO-SURGICAL APPARATUS AND RELATED METHODS
GB0407382D0 (en) Therapeutic methods and means
DE602005019913D1 (de) Therapeutische pyrazoloä3,4-büpyridine und -indazole
ZA200700749B (en) Methods and reagents for the treatment of metabolic disorders
EP1809276A4 (en) PROCESSING PROCESS
EP1653911A4 (en) METHODS OF TREATING METABOLIC SYNDROME
NO20050767D0 (no) Metode og utstyr for reduksjon av multiple dispersjoner